Zomiradomide is a PROTAC degradation agent targeting IRAK4, with oral bioavailability, and can also degrade Ikaros (IKZF1) and Aiolos (IKZF3), thereby inhibiting the NF-κB signalling pathway and activating the type I interferon signalling pathway, exhibiting anticancer activity against B-cell lymphoma.

Method:
The diffuse large B-cell lymphoma (DLBCL) cell line OCI-Ly10 carrying the Myd88 L265P mutation was treated with various concentrations of Zomiradomide to assess its antiproliferative effect and determine the IC₅₀ value.

Result:
Zomiradomide effectively inhibited the proliferation of OCI-Ly10 cells, with an IC₅₀ of 11 nM. [2]

Method:
In OCI-Ly10 xenograft mouse models, Zomiradomide was administered orally at doses of 3–30 mg/kg once daily for 3 consecutive days to evaluate its antitumor effect.

Result:
Zomiradomide significantly inhibited tumor growth. [2]